We are live on ! Find out more

Skye Bioscience

SKYE

Market cap $8.94M

2.02 USD

0.00

0%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

2.02

0.00

0%

1 day

0%

5 days

-16.53%

1 month

-59.44%

3 months

-69.3%

6 months

-67.26%

Year to date

-71.27%

1 year

-92.95%

5 years

-98.01%

10 years

-98.01%

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 12

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors Financings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028 Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ET SAN DIEGO and ALDERLEY PARK, United Kingdom, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, today announced that they have entered into a definitive transaction agreement (the “Transaction Agreement”).

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments.

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor.

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™